{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:59:22Z","timestamp":1776826762744,"version":"3.51.2"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[1998,3,1]],"date-time":"1998-03-01T00:00:00Z","timestamp":888710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[1998,3]]},"DOI":"10.1016\/s0002-9149(97)00965-x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T01:02:49Z","timestamp":1027645369000},"page":"582-587","source":"Crossref","is-referenced-by-count":797,"title":["Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997."],"prefix":"10.1016","volume":"81","author":[{"suffix":"MD","given":"Peter","family":"Jones","sequence":"first","affiliation":[]},{"suffix":"MD","given":"Stephanie","family":"Kafonek","sequence":"additional","affiliation":[]},{"suffix":"PharmD","given":"Irene","family":"Laurora","sequence":"additional","affiliation":[]},{"suffix":"MD","given":"Donald","family":"Hunninghake","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0002-9149(97)00965-X_BIB1","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","article-title":"Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)","volume":"269","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/clc.4960140211","article-title":"Once-daily pravastatin in patients with primary hypercholesterolemia","volume":"14","author":"Jones","year":"1991","journal-title":"Clin Cardiol"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00041433-199102000-00006","article-title":"HMG CoA reducatase inhibitors","volume":"2","author":"Illingworth","year":"1991","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB4","first-page":"366","article-title":"A review of clinical trials comparing HMG CoA reductase inhibitors","volume":"16","author":"Illingworth","year":"1994","journal-title":"Clin Ther"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0002-9149(97)89340-X","article-title":"Comparison of the effects on quality of life and the efficacy and tolerability of lovastatin versus pravastatin","volume":"77","author":"Weir","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/0002-9149(93)90601-8","article-title":"Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia","volume":"71","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000176682","article-title":"Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia","volume":"85","year":"1994","journal-title":"Cardiology"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF03259612","article-title":"Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia","volume":"6","author":"Douste-Blazy","year":"1993","journal-title":"Drug Invest"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/107424849600100105","article-title":"A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin","volume":"1","author":"Illingworth","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/107424849600100203","article-title":"A comparison of the tolerability and efficacy of lovastatin 20 mg and fluvastatin 20 mg in the treatment of primary hypercholesterolemia","volume":"1","author":"Berger","year":"1996","journal-title":"J Cardiovasc Pharmacol Therapeut"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB11","doi-asserted-by":"crossref","first-page":"54A","DOI":"10.1016\/S0002-9149(05)80018-9","article-title":"Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia","volume":"76","author":"Jacotot","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00044011-199612030-00001","article-title":"Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolemic patients","volume":"12","author":"Schulte","year":"1996","journal-title":"Clin Drug Invest"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1445-5994.1993.tb01439.x","article-title":"Treating hypercholesterolemia with HMG CoA reductase inhibitors","volume":"23","author":"Lintott","year":"1993","journal-title":"Aust N Z J Med"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","article-title":"Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor","volume":"15","author":"Nawrocki","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB15","unstructured":"Gmerek A, Yang R, Bays H, Jones P, Knopp R, Littlejohn T, Schrott H, Black D. Atorvastatin causes a dose-dependent reduction in LDL-C and triglycerides. In: 66th Congress of the European Artherosclerosis Society, July 1996:212."},{"key":"10.1016\/S0002-9149(97)00965-X_BIB16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0002-9149(97)00174-4","article-title":"Comparison of the one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia","volume":"79","author":"Davidson","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0021-9150(96)06052-2","article-title":"Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia","volume":"130","author":"Bertolini","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9149(97)00280-4","article-title":"A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia","volume":"80","author":"Dart","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-2712(18)30645-0","article-title":"The Centers for Disease Control\u2014National Heart, Lung, and Blood Institute Lipid Standardization Program","volume":"9","author":"Myers","year":"1989","journal-title":"Clin Lab Med"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB21","first-page":"850","article-title":"Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Research Clinics\u2019 methodology (abstr)","volume":"19","author":"Steiner","year":"1981","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/clinchem\/22.1.98","article-title":"Enzymatic determinations of cholesterol in high density lipoprotein fractions prepared by a precipitation technique","volume":"22","author":"Steele","year":"1976","journal-title":"Clin Chem"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A multiple comparison procedure for comparing several treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB24","doi-asserted-by":"crossref","first-page":"3D","DOI":"10.1016\/0002-9149(94)90626-2","article-title":"Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase","volume":"73","author":"Blum","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1991.00400010067008","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse events profile in 8245 patients with moderate hypercholesterolemia","volume":"151","author":"Bradford","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/S0002-9149(97)00965-X_BIB26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/106002809502907-818","article-title":"Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia","volume":"29","author":"Hsu","year":"1995","journal-title":"Ann Pharmacother"},{"issue":"suppl B","key":"10.1016\/S0002-9149(97)00965-X_BIB27","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1016\/0002-9343(91)90053-Z","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) study. IV. Additional perspectives on the tolerability of lovastatin","volume":"91","author":"Dujovne","year":"1991","journal-title":"Am J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291499700965X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291499700965X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T20:32:05Z","timestamp":1580848325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291499700965X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["S000291499700965X"],"URL":"https:\/\/doi.org\/10.1016\/s0002-9149(97)00965-x","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}